CHEMO AND ANTI-ESTROGEN THERAPY IN BREAST CANCER

乳腺癌的化疗和抗雌激素治疗

• 批准号: 3168969
• 负责人: JOSEPH P CROWE
• 金额: $ 23.62万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1981
• 资助国家: 美国
• 起止时间: 1981-09-01 至 1986-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3168969
• 关键词: breast neoplasms; breast surgery; combination cancer therapy; combination chemotherapy; cyclophosphamide; fluorouracil; human subject; methotrexate; neoplasm /cancer chemotherapy; neoplasm /cancer classification /staging; neoplasm /cancer immunotherapy; neoplasm /cancer surgery; sex cycle; tamoxifen

Eligible Stage II and III breast cancer patients who have had estrogen receptor assays done on the primary cancer after modified or radical mastectomy will be studied. It is our intent to observe the effect of adjuvant chemotherapy and anti-estrogen therapy in breast cancer patients, stratified by estrogen receptor assay: A. Positive node patients, whose primary tumors are estrogen receptor positive (ER+), will be classified as to their menopausal status. Eligible premenopausal ER+ patients will be subjected to surgical oophorectomy and randomized into one of two groups. One group will be given Tamoxifen for three years; the other group will be given 5-drug chemotherapy (CMFVP) + Tamoxifen for one year to be followed by Tamoxifen alone for the next two years. B. Postmenopausal Stage II patients, who are estrogen receptor positive (ER+), will be randomized between (a) Tamoxifen alone for three years and (b) 5-drug chemotherapy (CMFVP) + Tamoxifen for one year, followed by Tamoxifen alone for two years. C. Estrogen receptor negative (ER-) Stage II patients, both pre and postmenopausal, will be treated with 5-drug chemotherapy for one year postoperatively and followed until evidence of treatment failure occurs.

符合条件的II期和III期乳腺癌患者， 受体测定在原发癌上进行， 将研究乳房切除术。 我们的目的是观察 乳腺癌患者的辅助化疗和抗雌激素治疗， 通过雌激素受体测定分层：A. 阳性淋巴结患者， 原发性肿瘤为雌激素受体阳性（ER+），将被分类为 到更年期。 合格的绝经前ER+患者将 进行手术卵巢切除术并随机分为两组。 一组将给予他莫昔芬三年;另一组将给予他莫昔芬三年。 给予5种药物化疗（CMFVP）+他莫昔芬1年，随访 在接下来的两年里只服用他莫昔芬 B。 绝经后II期 雌激素受体阳性（ER+）的患者将被随机分组 （a）单独使用他莫昔芬三年和（B）5种药物化疗之间 （CMFVP）+他莫昔芬治疗1年，随后单独使用他莫昔芬治疗2年 年 C. 雌激素受体阴性（ER-）II期患者， 绝经后，将接受5种药物化疗一年 术后随访，直至出现治疗失败的证据。

项目成果

Primary tumor size. Relevance to breast cancer survival.

原发肿瘤大小。

• DOI: 10.1001/archsurg.1992.01420080044007
• 发表时间: 1992
• 期刊: Archives of surgery (Chicago, Ill. : 1960)
• 作者: CroweJr,JP;Gordon,NH;Shenk,RR;ZollingerJr,RM;Brumberg,DJ;Shuck,JM
• 通讯作者: Shuck,JM

Estrogen receptor determination and long term survival of patients with carcinoma of the breast.

• 发表时间: 1991-10
• 期刊: Surgery, gynecology & obstetrics
• 作者: Joseph P. Crowe;Nahida H. Gordon;Charles A. Hubay;Robert R. Shenk;Robert M. Zollinger;D. J. Brumberg;W. McGuire;Jerry M. Shuck

Endocrine versus endocrine plus five-drug chemotherapy in postmenopausal women with stage II estrogen receptor-positive breast cancer.

患有 II 期雌激素受体阳性乳腺癌的绝经后妇女的内分泌与内分泌加五药化疗的比较。

• DOI: 10.1002/1097-0142(19891101)64:9<1819::aid-cncr2820640910>3.0.co;2-n
• 发表时间: 1989
• 期刊: Cancer
• 影响因子: 6.2
• 作者: Pearson,OH;Hubay,CA;Gordon,NH;Marshall,JS;Crowe,JP;Arafah,BM;McGuire,W
• 通讯作者: McGuire,W

Local-regional breast cancer recurrence following mastectomy.

乳房切除术后局部区域乳腺癌复发。

• DOI: 10.1001/archsurg.1991.01410280027002
• 发表时间: 1991
• 期刊: Archives of surgery (Chicago, Ill. : 1960)
• 作者: CroweJr,JP;Gordon,NH;Antunez,AR;Shenk,RR;Hubay,CA;Shuck,JM
• 通讯作者: Shuck,JM